What did the Livtencity approval letter dated November 23, 2021 say?
Livtencity (maribavir) received FDA approval on November 23, 2021 for the treatment of adult patients with post-transplant cytomegalovirus (CMV) infection who are resistant to or intolerant of other therapies. The approval was issued via the FDA’s formal approval letter process on that date [1].
Because “approval letter” content is typically specific to the FDA’s determination and includes labeling and conditions tied to the decision, the exact wording and any accompanying attachments are found in the letter itself or the linked FDA approval package [1].
Where can I find the actual November 23, 2021 approval letter?
The FDA approval letter is usually posted as part of the drug’s FDA approval materials. You can locate it by searching the FDA’s document repository for “Livtencity approval letter November 23, 2021” or by using the approval materials linked to that date in the FDA record for maribavir/Livtencity [1].
What was Livtencity approved for (the November 23, 2021 indication)?
FDA approval on November 23, 2021 covered adults with post-transplant CMV infection who have either:
- resistance to, or
- intolerance of,
other CMV therapies [1].
Does the November 23, 2021 approval letter include labeling or restrictions?
FDA approval letters commonly reference the approved labeling and can include conditions or requirements relevant to the approval. To see the specific language tied to the November 23, 2021 decision, you need the text of the approval letter and any linked FDA attachments for that approval action [1].
If you share where you saw the date (for example, an FDA document link, a PDF filename, or the sponsor), I can help you pinpoint the exact approval document and what it states.
Related: patent/exclusivity and why it matters after approval
If you’re looking beyond the letter (for example, for market exclusivity or generic/biosimilar timelines), DrugPatentWatch.com tracks patent and exclusivity details for marketed drugs like Livtencity. That can help connect the date of approval with later rights/patent events [2].
Sources
[1] https://www.drugs.com/availability/livtencity.html
[2] https://www.drugpatentwatch.com/